메뉴 건너뛰기




Volumn 3, Issue , 2010, Pages 227-246

The spectrum of use of rituximab in chronic lymphocytic leukemia

Author keywords

B cell chronic lymphocytic leukemia; First line treatment; Refractory relapsed; Rituximab

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; FLUDARABINE; FOSCARNET; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LENALIDOMIDE; LUMILIXIMAB; METHYLPREDNISOLONE; MITOXANTRONE; MONOCLONAL ANTIBODY; OXALIPLATIN; PENTOSTATIN; PURINE DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

EID: 84863828006     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (6)

References (136)
  • 1
    • 84863828634 scopus 로고    scopus 로고
    • National Cancer Institute SEER Cancer Statistics Review 1975-2007, Accessed 2010 Oct 30
    • National Cancer Institute SEER Cancer Statistics Review 1975-2007. http://seer.cancer.gov/csr/1975_2007/. Accessed 2010 Oct 30.
  • 2
    • 40749132494 scopus 로고    scopus 로고
    • Chronic lymphocytic leukaemia
    • Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet. 2008;371:1017-1029.
    • (2008) Lancet , vol.371 , pp. 1017-1029
    • Dighiero, G.1    Hamblin, T.J.2
  • 3
    • 0019427092 scopus 로고
    • A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis
    • Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198-206.
    • (1981) Cancer , vol.48 , pp. 198-206
    • Binet, J.L.1    Auquier, A.2    Dighiero, G.3
  • 4
    • 0016740933 scopus 로고
    • Clinical staging of chronic lymphocytic leukemia
    • Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219-234.
    • (1975) Blood , vol.46 , pp. 219-234
    • Rai, K.R.1    Sawitsky, A.2    Cronkite, E.P.3
  • 5
    • 15244342190 scopus 로고    scopus 로고
    • Chronic lymphocytic leukemia: Novel prognostic factors and their relevance for risk-adapted therapeutic strategies
    • Montillo M, Hamblin T, Hallek M, et al. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica. 2005;90:391-399.
    • (2005) Haematologica , vol.90 , pp. 391-399
    • Montillo, M.1    Hamblin, T.2    Hallek, M.3
  • 6
    • 85047683837 scopus 로고    scopus 로고
    • Classical and new prognostic factors in chronic lymphocytic leukemia: Where to now?
    • Montserrat E. Classical and new prognostic factors in chronic lymphocytic leukemia: where to now? Hematol J. 2002;3:7-9.
    • (2002) Hematol J , vol.3 , pp. 7-9
    • Montserrat, E.1
  • 7
    • 0034727833 scopus 로고    scopus 로고
    • Genomic aberrations and survival in chronic lymphocytic leukemia
    • Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343: 1910-1916.
    • (2000) N Engl J Med , vol.343 , pp. 1910-1916
    • Dohner, H.1    Stilgenbauer, S.2    Benner, A.3
  • 8
    • 0033567968 scopus 로고    scopus 로고
    • Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia
    • Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840-1847.
    • (1999) Blood , vol.94 , pp. 1840-1847
    • Damle, R.N.1    Wasil, T.2    Fais, F.3
  • 9
    • 0033567907 scopus 로고    scopus 로고
    • Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia
    • Hamblin T, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848-1854.
    • (1999) Blood , vol.94 , pp. 1848-1854
    • Hamblin, T.1    Davis, Z.2    Gardiner, A.3
  • 10
    • 0037406968 scopus 로고    scopus 로고
    • ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia
    • Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764-1775.
    • (2003) N Engl J Med , vol.348 , pp. 1764-1775
    • Crespo, M.1    Bosch, F.2    Villamor, N.3
  • 11
    • 0024379558 scopus 로고
    • Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia
    • di Giovanni S, Valentini G, Carducci P, et al. Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia. Acta Haematol. 1989;81:181-185.
    • (1989) Acta Haematol , vol.81 , pp. 181-185
    • di Giovanni, S.1    Valentini, G.2    Carducci, P.3
  • 12
    • 0033583824 scopus 로고    scopus 로고
    • Chemotherapeutic options in chronic lymphocytic leukemia: A meta-analysis of the randomized trials. CLL Trialists' Collaborative Group
    • CLL Trialists' Collaborative Group
    • CLL Trialists' Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Inst. 1999;91: 861-868.
    • (1999) J Natl Cancer Inst , vol.91 , pp. 861-868
  • 13
    • 0029981025 scopus 로고    scopus 로고
    • National Cancer Institutesponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
    • Cheson BD, Bennet JM, Grever M, et al. National Cancer Institutesponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87:4990-4997.
    • (1996) Blood , vol.87 , pp. 4990-4997
    • Cheson, B.D.1    Bennet, J.M.2    Grever, M.3
  • 14
    • 45149100665 scopus 로고    scopus 로고
    • Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
    • Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446-5456.
    • (2008) Blood , vol.111 , pp. 5446-5456
    • Hallek, M.1    Cheson, B.D.2    Catovsky, D.3
  • 15
    • 0027200169 scopus 로고
    • Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent
    • Keating MJ, O'Brien S, Kantariian,et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood. 1993;81:2878-2884.
    • (1993) Blood , vol.81 , pp. 2878-2884
    • Keating, M.J.1    O'Brien, S.2    Kantariian3
  • 16
    • 0034649696 scopus 로고    scopus 로고
    • Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
    • Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750-1757.
    • (2000) N Engl J Med , vol.343 , pp. 1750-1757
    • Rai, K.R.1    Peterson, B.L.2    Appelbaum, F.R.3
  • 17
    • 15844368449 scopus 로고    scopus 로고
    • Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL
    • Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet. 1996;347:1432-1438.
    • (1996) Lancet , vol.347 , pp. 1432-1438
    • Johnson, S.1    Smith, A.G.2    Loffler, H.3
  • 18
    • 0035889147 scopus 로고    scopus 로고
    • Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients
    • Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 2001;98:2319-2325.
    • (2001) Blood , vol.98 , pp. 2319-2325
    • Leporrier, M.1    Chevret, S.2    Cazin, B.3
  • 19
    • 0032529509 scopus 로고    scopus 로고
    • Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy
    • Keating MJ, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998;92:1165-1171.
    • (1998) Blood , vol.92 , pp. 1165-1171
    • Keating, M.J.1    O'Brien, S.2    Lerner, S.3
  • 20
    • 34447530283 scopus 로고    scopus 로고
    • Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial
    • Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007; 370:230-239.
    • (2007) Lancet , vol.370 , pp. 230-239
    • Catovsky, D.1    Richards, S.2    Matutes, E.3
  • 21
    • 18744409028 scopus 로고    scopus 로고
    • Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia
    • Bosch F, Ferrer A, Lopez-Guillermo A, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol. 2002;119:976-984.
    • (2002) Br J Haematol , vol.119 , pp. 976-984
    • Bosch, F.1    Ferrer, A.2    Lopez-Guillermo, A.3
  • 22
    • 33745985715 scopus 로고    scopus 로고
    • Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: A systematic review and meta-analysis
    • Steurer M, Pall G, Richards S, et al. Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis. Cancer Treat Rev. 2006;32:377-389.
    • (2006) Cancer Treat Rev , vol.32 , pp. 377-389
    • Steurer, M.1    Pall, G.2    Richards, S.3
  • 23
    • 11144357712 scopus 로고    scopus 로고
    • Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia
    • Keating MJ, Coutrè S, Rai K, et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma. 2004;4:220-227.
    • (2004) Clin Lymphoma , vol.4 , pp. 220-227
    • Keating, M.J.1    Coutrè, S.2    Rai, K.3
  • 24
    • 0037297313 scopus 로고    scopus 로고
    • Rituximab in chronic lymphocytic leukemia
    • Montserrat E. Rituximab in chronic lymphocytic leukemia. Semin Oncol. 2003;30:34-39.
    • (2003) Semin Oncol , vol.30 , pp. 34-39
    • Montserrat, E.1
  • 25
    • 0034894958 scopus 로고    scopus 로고
    • Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis
    • Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res. 2001;7: 709-723.
    • (2001) Clin Cancer Res , vol.7 , pp. 709-723
    • Alas, S.1    Emmanouilides, C.2    Bonavida, B.3
  • 26
    • 0034796371 scopus 로고    scopus 로고
    • Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant ot the cytotoxic activity of either drug alone
    • di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant ot the cytotoxic activity of either drug alone. Br J Haematol. 2001;114: 800-809.
    • (2001) Br J Haematol , vol.114 , pp. 800-809
    • di Gaetano, N.1    Xiao, Y.2    Erba, E.3
  • 27
    • 51649093353 scopus 로고    scopus 로고
    • Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
    • Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112:975-980.
    • (2008) Blood , vol.112 , pp. 975-980
    • Tam, C.S.1    O'Brien, S.2    Wierda, W.3
  • 28
    • 77950478885 scopus 로고    scopus 로고
    • Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia
    • Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1756-1765.
    • (2010) J Clin Oncol , vol.28 , pp. 1756-1765
    • Robak, T.1    Dmoszynska, A.2    Solal-Celigny, P.3
  • 29
    • 77949479415 scopus 로고    scopus 로고
    • State-of-the-art treatment of chronic lymphocytic leukemia
    • Hallek M. State-of-the-art treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2009;440-449.
    • (2009) Hematology Am Soc Hematol Educ Program , pp. 440-449
    • Hallek, M.1
  • 30
    • 23044510136 scopus 로고    scopus 로고
    • Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
    • Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005; 23:4079-4088.
    • (2005) J Clin Oncol , vol.23 , pp. 4079-4088
    • Keating, M.J.1    O'Brien, S.2    Albitar, M.3
  • 31
    • 76949091824 scopus 로고    scopus 로고
    • First-line treatment with fludarabine (f), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): Results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group
    • Abstract 535
    • Hallek M, Fingerle-Rowson G, Fink AM, et al. First-line treatment with fludarabine (f), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group. Blood. 2009;114:Abstract 535.
    • (2009) Blood , vol.114
    • Hallek, M.1    Fingerle-Rowson, G.2    Fink, A.M.3
  • 32
    • 21144456107 scopus 로고    scopus 로고
    • Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival
    • Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol. 2005;23: 2971-2979.
    • (2005) J Clin Oncol , vol.23 , pp. 2971-2979
    • Moreton, P.1    Kennedy, B.2    Lucas, G.3
  • 33
    • 33845543049 scopus 로고    scopus 로고
    • Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: The EBMT transplant consensus
    • Dreger P, Corradini P, Kimby E, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007;21:12-17.
    • (2007) Leukemia , vol.21 , pp. 12-17
    • Dreger, P.1    Corradini, P.2    Kimby, E.3
  • 34
    • 0141568894 scopus 로고    scopus 로고
    • Rituximab and other emerging antibodies as molecular targetbased therapy of lymphoma
    • Tobinai K. Rituximab and other emerging antibodies as molecular targetbased therapy of lymphoma. Int J Clin Oncol. 2003;8:212-223.
    • (2003) Int J Clin Oncol , vol.8 , pp. 212-223
    • Tobinai, K.1
  • 35
    • 0642312825 scopus 로고    scopus 로고
    • Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance
    • Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359-7368.
    • (2003) Oncogene , vol.22 , pp. 7359-7368
    • Smith, M.R.1
  • 36
    • 0031837813 scopus 로고    scopus 로고
    • Levels of expression of CD19 and CD20 in chronic B cell leukaemias
    • Ginaldi L, de Martinis M, Matutes E, et al. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol. 1998;51: 364-369.
    • (1998) J Clin Pathol , vol.51 , pp. 364-369
    • Ginaldi, L.1    de Martinis, M.2    Matutes, E.3
  • 37
    • 34548221347 scopus 로고    scopus 로고
    • Mechanisms of killing by anti- CD20 monoclonal antibodies
    • Glennie MJ, French RR, Cragg MS, et al. Mechanisms of killing by anti- CD20 monoclonal antibodies. Mol Immunol. 2007;44:3823-3837.
    • (2007) Mol Immunol , vol.44 , pp. 3823-3837
    • Glennie, M.J.1    French, R.R.2    Cragg, M.S.3
  • 38
    • 16544389341 scopus 로고    scopus 로고
    • The biology of CD20 and its potential as a target for mAb therapy
    • Cragg MS, Walshe CA, Ivanoy AO, et al. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 2005; 8:140-174.
    • (2005) Curr Dir Autoimmun , vol.8 , pp. 140-174
    • Cragg, M.S.1    Walshe, C.A.2    Ivanoy, A.O.3
  • 39
    • 0030800131 scopus 로고    scopus 로고
    • Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
    • Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm. 1997;12:177-186.
    • (1997) Cancer Biother Radiopharm , vol.12 , pp. 177-186
    • Demidem, A.1    Lam, T.2    Alas, S.3
  • 40
    • 0037306893 scopus 로고    scopus 로고
    • In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
    • Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003;101: 949-954.
    • (2003) Blood , vol.101 , pp. 949-954
    • Manches, O.1    Lui, G.2    Chaperot, L.3
  • 41
    • 0034091481 scopus 로고    scopus 로고
    • Rituximab (anti-CD20) therapy of B-cell lymphomas: Direct complement killing is superior to cellular effector mechanisms
    • Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol. 2000;51:634-641.
    • (2000) Scand J Immunol , vol.51 , pp. 634-641
    • Harjunpaa, A.1    Junnikkala, S.2    Meri, S.3
  • 42
    • 0036464719 scopus 로고    scopus 로고
    • Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene
    • Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754-758.
    • (2002) Blood , vol.99 , pp. 754-758
    • Cartron, G.1    Dacheux, L.2    Salles, G.3
  • 43
    • 0842264005 scopus 로고    scopus 로고
    • Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia
    • Farag SS, Flinn IW, Modali R, et al. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood. 2004;103:1472-1474.
    • (2004) Blood , vol.103 , pp. 1472-1474
    • Farag, S.S.1    Flinn, I.W.2    Modali, R.3
  • 44
    • 0034999619 scopus 로고    scopus 로고
    • Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies
    • Treon SP, Mitsiades C, Mitsiades N, et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother. 2001;24:263-271.
    • (2001) J Immunother , vol.24 , pp. 263-271
    • Treon, S.P.1    Mitsiades, C.2    Mitsiades, N.3
  • 45
    • 0034660092 scopus 로고    scopus 로고
    • Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
    • Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95: 3900-3908.
    • (2000) Blood , vol.95 , pp. 3900-3908
    • Golay, J.1    Zaffaroni, L.2    Vaccari, T.3
  • 46
    • 0034660092 scopus 로고    scopus 로고
    • Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
    • Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95:3900-3908.
    • (2000) Blood , vol.95 , pp. 3900-3908
    • Golay, J.1    Zaffaroni, L.2    Vaccari, T.3
  • 47
    • 0037108441 scopus 로고    scopus 로고
    • The triterpenoid CDDO induces apoptosis in refractory CLL B cells
    • Pedersen IM, Kitada S, Schimmer A, et al. The triterpenoid CDDO induces apoptosis in refractory CLL B cells. Blood. 2002;100:2965-2972.
    • (2002) Blood , vol.100 , pp. 2965-2972
    • Pedersen, I.M.1    Kitada, S.2    Schimmer, A.3
  • 48
    • 0036266736 scopus 로고    scopus 로고
    • Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?
    • Selenko N, Majdic O, Jager U, et al. Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies? J Clin Immunol. 2002;22:124-130.
    • (2002) J Clin Immunol , vol.22 , pp. 124-130
    • Selenko, N.1    Majdic, O.2    Jager, U.3
  • 49
    • 0034777814 scopus 로고    scopus 로고
    • CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells
    • Selenko N, Majdic O, Draxier S, et al. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia. 2001;15: 1619-1626.
    • (2001) Leukemia , vol.15 , pp. 1619-1626
    • Selenko, N.1    Majdic, O.2    Draxier, S.3
  • 50
    • 17144455839 scopus 로고    scopus 로고
    • IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
    • Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997;15:3266-3274.
    • (1997) J Clin Oncol , vol.15 , pp. 3266-3274
    • Maloney, D.G.1    Grillo-Lopez, A.J.2    Bodkin, D.J.3
  • 51
    • 0033968522 scopus 로고    scopus 로고
    • European phase II study of Rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma, immunocytoma and small B-cell lymphocytic lymphoma
    • Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of Rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma, immunocytoma and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18:317-324.
    • (2000) J Clin Oncol , vol.18 , pp. 317-324
    • Foran, J.M.1    Rohatiner, A.Z.2    Cunningham, D.3
  • 52
    • 0345337254 scopus 로고    scopus 로고
    • Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
    • McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol.1998;16:2825-2833.
    • (1998) J Clin Oncol , vol.16 , pp. 2825-2833
    • McLaughlin, P.1    Grillo-Lopez, A.J.2    Link, B.K.3
  • 53
    • 0033214207 scopus 로고    scopus 로고
    • Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8)
    • Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood. 1999;94:2217-2224.
    • (1999) Blood , vol.94 , pp. 2217-2224
    • Winkler, U.1    Jensen, M.2    Manzke, O.3
  • 54
    • 0032931320 scopus 로고    scopus 로고
    • IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: Evaluation of response on 48 patients
    • Nguyen DT, Amess JA, Doughty H, et al. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: Evaluation of response on 48 patients. Eur J Haematol.1999;62:76-82.
    • (1999) Eur J Haematol , vol.62 , pp. 76-82
    • Nguyen, D.T.1    Amess, J.A.2    Doughty, H.3
  • 55
    • 0035469851 scopus 로고    scopus 로고
    • Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
    • Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood. 2001;98:1326-1331.
    • (2001) Blood , vol.98 , pp. 1326-1331
    • Huhn, D.1    von Schilling, C.2    Wilhelm, M.3
  • 56
    • 0036757311 scopus 로고    scopus 로고
    • Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: Results from a Nordic multicentre study
    • Itala M, Geisler CH, Kimby E, et al. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur J Haematol. 2002;69:129-134.
    • (2002) Eur J Haematol , vol.69 , pp. 129-134
    • Itala, M.1    Geisler, C.H.2    Kimby, E.3
  • 57
    • 0035871441 scopus 로고    scopus 로고
    • Rituximab doseescalation trial in chronic lymphocytic leukemia
    • O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab doseescalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19: 2165-2170.
    • (2001) J Clin Oncol , vol.19 , pp. 2165-2170
    • O'Brien, S.M.1    Kantarjian, H.2    Thomas, D.A.3
  • 58
    • 0035871445 scopus 로고    scopus 로고
    • Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity
    • Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001;19:2153-2164.
    • (2001) J Clin Oncol , vol.19 , pp. 2153-2164
    • Byrd, J.C.1    Murphy, T.2    Howard, R.S.3
  • 59
    • 0038811776 scopus 로고    scopus 로고
    • Single-agent rituximab as firstline and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network
    • Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as firstline and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003;21:1746-1751.
    • (2003) J Clin Oncol , vol.21 , pp. 1746-1751
    • Hainsworth, J.D.1    Litchy, S.2    Barton, J.H.3
  • 60
    • 79951658129 scopus 로고    scopus 로고
    • Single agent rituximab in early stage chronic lymphocytic leukemia
    • Thomas DA, O'Brien S, Giles FJ, et al. Single agent rituximab in early stage chronic lymphocytic leukemia. Blood. 2001;98:364a.
    • (2001) Blood , vol.98
    • Thomas, D.A.1    O'Brien, S.2    Giles, F.J.3
  • 61
    • 0034649696 scopus 로고    scopus 로고
    • Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
    • Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750-1757.
    • (2000) N Engl J Med , vol.343 , pp. 1750-1757
    • Rai, K.R.1    Peterson, B.L.2    Appelbaum, F.R.3
  • 62
    • 0036125566 scopus 로고    scopus 로고
    • Level of CD20 expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukaemia and B-cell chronic lymphocytic leukaemia
    • Perz J, Topaly J, Fruehauf S, et al. Level of CD20 expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukaemia and B-cell chronic lymphocytic leukaemia. Leuk Lymphoma. 2002;43:149-151.
    • (2002) Leuk Lymphoma , vol.43 , pp. 149-151
    • Perz, J.1    Topaly, J.2    Fruehauf, S.3
  • 63
    • 0038446696 scopus 로고    scopus 로고
    • Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance
    • Manshouri T. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood. 2003;101:2507-2513.
    • (2003) Blood , vol.101 , pp. 2507-2513
    • Manshouri, T.1
  • 64
    • 17144455839 scopus 로고    scopus 로고
    • IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
    • Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol.1997;15:3266-3274.
    • (1997) J Clin Oncol , vol.15 , pp. 3266-3274
    • Maloney, D.G.1    Grillo-Lopez, A.J.2    Bodkin, D.J.3
  • 65
    • 74949089578 scopus 로고    scopus 로고
    • Low-dose fludarabine increases rituximab cytotoxicity in B-CLL cells by triggering caspases activation in vitro
    • Furlan A, Villanova F, Pietrogrande F, et al. Low-dose fludarabine increases rituximab cytotoxicity in B-CLL cells by triggering caspases activation in vitro. Leuk Lymphoma. 2010;51:107-113.
    • (2010) Leuk Lymphoma , vol.51 , pp. 107-113
    • Furlan, A.1    Villanova, F.2    Pietrogrande, F.3
  • 66
    • 0036154263 scopus 로고    scopus 로고
    • Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement, and caspases
    • Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica. 2002;87:33-43.
    • (2002) Haematologica , vol.87 , pp. 33-43
    • Chow, K.U.1    Sommerlad, W.D.2    Boehrer, S.3
  • 67
    • 0037220152 scopus 로고    scopus 로고
    • Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712)
    • Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101:6-14.
    • (2003) Blood , vol.101 , pp. 6-14
    • Byrd, J.C.1    Peterson, B.L.2    Morrison, V.A.3
  • 68
    • 77950314844 scopus 로고    scopus 로고
    • Treatment with fludarabine and rituximab produces extended overall survival (OS) and Progression- Free Survival (PFS) in chronic lymphocytic leukemia (CLL) without increased risk of second malignancy: Long-term follow up of CALGB study 9712
    • Abstract 539
    • Woyach JA, Ruppert AS, Heerema NA, et al. Treatment with fludarabine and rituximab produces extended overall survival (OS) and Progression- Free Survival (PFS) in chronic lymphocytic leukemia (CLL) without increased risk of second malignancy: long-term follow up of CALGB study 9712. Blood. 2009;114:Abstract 539.
    • (2009) Blood , vol.114
    • Woyach, J.A.1    Ruppert, A.S.2    Heerema, N.A.3
  • 69
    • 19944429446 scopus 로고    scopus 로고
    • Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
    • Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105:49-53.
    • (2005) Blood , vol.105 , pp. 49-53
    • Byrd, J.C.1    Rai, K.2    Peterson, B.L.3
  • 70
    • 0036839469 scopus 로고    scopus 로고
    • Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia
    • Schulz H, Klein SK, Rehwald U, et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood. 2002;100:3115-3120.
    • (2002) Blood , vol.100 , pp. 3115-3120
    • Schulz, H.1    Klein, S.K.2    Rehwald, U.3
  • 71
    • 0034893776 scopus 로고    scopus 로고
    • Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): Results of a phase II study of the German CLL Study Group
    • Hallek M, Schmitt B, Wilhelm M, et al. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. Br J Haematol. 2001;114:342-348.
    • (2001) Br J Haematol , vol.114 , pp. 342-348
    • Hallek, M.1    Schmitt, B.2    Wilhelm, M.3
  • 72
    • 0034235909 scopus 로고    scopus 로고
    • Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies
    • Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood. 2000;96:71-75.
    • (2000) Blood , vol.96 , pp. 71-75
    • Flinn, I.W.1    Byrd, J.C.2    Morrison, C.3
  • 73
    • 0035282055 scopus 로고    scopus 로고
    • Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia
    • O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:1414-1420.
    • (2001) J Clin Oncol , vol.19 , pp. 1414-1420
    • O'Brien, S.M.1    Kantarjian, H.M.2    Cortes, J.3
  • 74
    • 23044501404 scopus 로고    scopus 로고
    • Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
    • Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4070-4078.
    • (2005) J Clin Oncol , vol.23 , pp. 4070-4078
    • Wierda, W.1    O'Brien, S.2    Wen, S.3
  • 75
    • 0037092951 scopus 로고    scopus 로고
    • Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study
    • Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554-3561.
    • (2002) Blood , vol.99 , pp. 3554-3561
    • Keating, M.J.1    Flinn, I.2    Jain, V.3
  • 76
    • 0037106502 scopus 로고    scopus 로고
    • Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine
    • Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002;20:3891-3897.
    • (2002) J Clin Oncol , vol.20 , pp. 3891-3897
    • Rai, K.R.1    Freter, C.E.2    Mercier, R.J.3
  • 77
    • 59449110380 scopus 로고    scopus 로고
    • Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia
    • Tsimberodou AM, Tam C, Abruzzo LV, et al. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer. 2009;115:373-380.
    • (2009) Cancer , vol.115 , pp. 373-380
    • Tsimberodou, A.M.1    Tam, C.2    Abruzzo, L.V.3
  • 78
    • 30744448409 scopus 로고    scopus 로고
    • A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens
    • Wierda W, O'Brien S, Faderl S, et al. A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer. 2006;106:337-345.
    • (2006) Cancer , vol.106 , pp. 337-345
    • Wierda, W.1    O'Brien, S.2    Faderl, S.3
  • 79
    • 61849091076 scopus 로고    scopus 로고
    • Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL)
    • Abstract 325
    • Hallek M, Fingerle-Rowson G, Fink AM, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood. 2008; 112:Abstract 325.
    • (2008) Blood , vol.112
    • Hallek, M.1    Fingerle-Rowson, G.2    Fink, A.M.3
  • 80
    • 77950308297 scopus 로고    scopus 로고
    • "Groupe Ouest-Est d'Etudes Des Leucémies Aigües Et Autres Maladies Du sang" (GOELAMS):CLL2007FMP (for fit medically patients)
    • Abstract 538 Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine (F), cyclophosphamide (C) and mabcampath (Cam) (FCCam) in previously untreated patients (pts) with advanced B-chronic lymphocytic leukemia (B-CLL): Experience on safety and efficacy within a randomised multicenter phase III trial of the French Cooperative Group on CLL and WM (FCGCLL/MW) and the
    • Lepretre S, Aurran T, Mahe B, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine (F), cyclophosphamide (C) and mabcampath (Cam) (FCCam) in previously untreated patients (pts) with advanced B-chronic lymphocytic leukemia (B-CLL): experience on safety and efficacy within a randomised multicenter phase III trial of the French Cooperative Group on CLL and WM (FCGCLL/MW) and the "Groupe Ouest-Est d'Etudes Des Leucémies Aigües Et Autres Maladies Du sang" (GOELAMS):CLL2007FMP (for fit medically patients). Blood. 2009;114:Abstract 538.
    • (2009) Blood , vol.114
    • Lepretre, S.1    Aurran, T.2    Mahe, B.3
  • 81
    • 59149090791 scopus 로고    scopus 로고
    • Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia
    • Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27:498-503.
    • (2009) J Clin Oncol , vol.27 , pp. 498-503
    • Foon, K.A.1    Boyiadzis, M.2    Land, S.R.3
  • 82
    • 59149106873 scopus 로고    scopus 로고
    • Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: Molecular remissions predict for durable complete responses
    • Lamanna N, Jurcic JG, Nov A, et al. Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol. 2009;27:491-497.
    • (2009) J Clin Oncol , vol.27 , pp. 491-497
    • Lamanna, N.1    Jurcic, J.G.2    Nov, A.3
  • 83
    • 0038514130 scopus 로고    scopus 로고
    • Pentostatin and cyclophosphamide: An effective new regimen in previously treated patients with chronic lymphocytic leukemia
    • Weiss MA, Maslak PG, Jurcic JG, et al. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol. 2003;21: 1278-1284.
    • (2003) J Clin Oncol , vol.21 , pp. 1278-1284
    • Weiss, M.A.1    Maslak, P.G.2    Jurcic, J.G.3
  • 84
    • 33645732715 scopus 로고    scopus 로고
    • Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia
    • Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2006;24:1575-1581.
    • (2006) J Clin Oncol , vol.24 , pp. 1575-1581
    • Lamanna, N.1    Kalaycio, M.2    Maslak, P.3
  • 85
    • 33846258434 scopus 로고    scopus 로고
    • Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
    • Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood. 2007; 109:405-411.
    • (2007) Blood , vol.109 , pp. 405-411
    • Kay, N.E.1    Geyer, S.M.2    Call, T.G.3
  • 86
    • 34249042684 scopus 로고    scopus 로고
    • Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia
    • Shanafelt TD, Lin T, Geyer SM, et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer. 2007;109:2291-2298.
    • (2007) Cancer , vol.109 , pp. 2291-2298
    • Shanafelt, T.D.1    Lin, T.2    Geyer, S.M.3
  • 87
    • 67749097105 scopus 로고    scopus 로고
    • Phase III trial of fludarabine, cyclophosphamide, and rituximab vs pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia
    • Abstract 126
    • Reynolds C, di Bella N, Lyons RM, et al. Phase III trial of fludarabine, cyclophosphamide, and rituximab vs pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Blood. 2008; 112:Abstract 126.
    • (2008) Blood , vol.112
    • Reynolds, C.1    di Bella, N.2    Lyons, R.M.3
  • 88
    • 77951456080 scopus 로고    scopus 로고
    • Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia
    • Kay NE, Wu W, Kabat B, et al. Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. Cancer. 2010;116:2180-2187.
    • (2010) Cancer , vol.116 , pp. 2180-2187
    • Kay, N.E.1    Wu, W.2    Kabat, B.3
  • 89
    • 34447326480 scopus 로고    scopus 로고
    • Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia
    • Robak T, Smolewski P, Cebula B, et al. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. Eur J Haematol. 2007;79: 107-113.
    • (2007) Eur J Haematol , vol.79 , pp. 107-113
    • Robak, T.1    Smolewski, P.2    Cebula, B.3
  • 90
    • 77955449996 scopus 로고    scopus 로고
    • Riruximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients
    • Bertazzoni P, Rabascio C, Gigli F, et al. Riruximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients. Leuk Lymphoma. 2010;51:1485-1493.
    • (2010) Leuk Lymphoma , vol.51 , pp. 1485-1493
    • Bertazzoni, P.1    Rabascio, C.2    Gigli, F.3
  • 91
    • 77953441848 scopus 로고    scopus 로고
    • Bendamustine: New perspective for an old drug in lymphoproliferative disorders
    • Montillo M, Ricci F, Tedeschi A, et al. Bendamustine: new perspective for an old drug in lymphoproliferative disorders. Expert Rev Hematol. 2010;3:131-148.
    • (2010) Expert Rev Hematol , vol.3 , pp. 131-148
    • Montillo, M.1    Ricci, F.2    Tedeschi, A.3
  • 92
    • 65749110753 scopus 로고    scopus 로고
    • Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic Leukemia (CLL): A multicentre phase II trial of the German CLL Study Group (GCLLSG)
    • Abstract 330
    • Fischer K, Stilgenbauer S, Schweighofer CD, et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic Leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG). Blood. 2008;112: Abstract 330.
    • (2008) Blood , vol.112
    • Fischer, K.1    Stilgenbauer, S.2    Schweighofer, C.D.3
  • 93
    • 77950321929 scopus 로고    scopus 로고
    • Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: A multicenter phase II trial of the German CLL Study Group (GCLLSG)
    • Abstract 205
    • Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: A multicenter phase II trial of the German CLL Study Group (GCLLSG). Blood. 2009;114:Abstract 205.
    • (2009) Blood , vol.114
    • Fischer, K.1    Cramer, P.2    Stilgenbauer, S.3
  • 94
    • 34447549127 scopus 로고    scopus 로고
    • High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)
    • Weide R, Hess G, Koppler H, et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma. 2007;48:1299-1306.
    • (2007) Leuk Lymphoma , vol.48 , pp. 1299-1306
    • Weide, R.1    Hess, G.2    Koppler, H.3
  • 95
    • 77956198078 scopus 로고    scopus 로고
    • An open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukaemia (CLL)
    • Abstract 3428
    • Hillmen P, Gribben JG, MD, Follows GA, et al. An open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukaemia (CLL). Blood. 2009;114: Abstract 3428.
    • (2009) Blood , vol.114
    • Hillmen, P.1    Gribben, J.G.2    Follows, G.A.M.D.3
  • 96
    • 40749128044 scopus 로고    scopus 로고
    • Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: High response rate and disease eradication
    • Bosch F, Ferrer A, Villamor N, et al. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res. 2008; 14:155-1561.
    • (2008) Clin Cancer Res , vol.14 , pp. 155-1561
    • Bosch, F.1    Ferrer, A.2    Villamor, N.3
  • 97
    • 1842450530 scopus 로고    scopus 로고
    • Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma
    • Hendry L, Bowen A, Matutes E, et al. Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma. Leuk Lymphoma. 2004;45:945-950.
    • (2004) Leuk Lymphoma , vol.45 , pp. 945-950
    • Hendry, L.1    Bowen, A.2    Matutes, E.3
  • 98
    • 77950546050 scopus 로고    scopus 로고
    • NCRI CLL201 Trial: A randomized phase ii trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated CLL
    • Abstract 752
    • Hillmen P, Pocock C, Cohen D, et al. NCRI CLL201 Trial: a randomized phase ii trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated CLL. Blood. 2007;110:Abstract 752.
    • (2007) Blood , vol.110
    • Hillmen, P.1    Pocock, C.2    Cohen, D.3
  • 99
    • 74549145611 scopus 로고    scopus 로고
    • Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: A new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia
    • Bosch F, Abrisqueta P, Villamor N, et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol. 2009;27:4578-4584.
    • (2009) J Clin Oncol , vol.27 , pp. 4578-4584
    • Bosch, F.1    Abrisqueta, P.2    Villamor, N.3
  • 100
    • 77649184591 scopus 로고    scopus 로고
    • Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL, 70 years
    • Faderl S, Wierda W, O'Brien S, et al. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL, 70 years. Leuk Res. 2010;34:284-288.
    • (2010) Leuk Res , vol.34 , pp. 284-288
    • Faderl, S.1    Wierda, W.2    O'Brien, S.3
  • 101
    • 38349163290 scopus 로고    scopus 로고
    • Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia
    • Tsimberidou AM, Wierda W, Plunkett W, et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008;26(2):196-203.
    • (2008) J Clin Oncol , vol.26 , Issue.2 , pp. 196-203
    • Tsimberidou, A.M.1    Wierda, W.2    Plunkett, W.3
  • 102
    • 0036239496 scopus 로고    scopus 로고
    • Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders
    • Tsimberidou AM, O'Brien SM, Cortes JE, et al. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma. 2002;43: 767-772.
    • (2002) Leuk Lymphoma , vol.43 , pp. 767-772
    • Tsimberidou, A.M.1    O'Brien, S.M.2    Cortes, J.E.3
  • 103
    • 0033406619 scopus 로고    scopus 로고
    • Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: A phase II study
    • Giles FJ, O'Brien SM, Santini V, et al. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study. Leuk Lymphoma. 1999;36:57-65.
    • (1999) Leuk Lymphoma , vol.36 , pp. 57-65
    • Giles, F.J.1    O'Brien, S.M.2    Santini, V.3
  • 104
    • 79955817096 scopus 로고    scopus 로고
    • Oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy induces high response rates in agressive chronic lymphocytic Leukemia (CLL) and Richter's syndrome (RS)
    • Abstract 3443
    • Tsimberidou AM, Wierda W, Plunkett W, et al. Oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy induces high response rates in agressive chronic lymphocytic Leukemia (CLL) and Richter's syndrome (RS). Blood. 2009;114:Abstract 3443.
    • (2009) Blood , vol.114
    • Tsimberidou, A.M.1    Wierda, W.2    Plunkett, W.3
  • 105
    • 0034775122 scopus 로고    scopus 로고
    • Variability in B-cell antigen expression: Implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies
    • Rossmann ED, Lundin J, Lenkei R, et al. Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J. 2001;2: 300-306.
    • (2001) Hematol J , vol.2 , pp. 300-306
    • Rossmann, E.D.1    Lundin, J.2    Lenkei, R.3
  • 106
    • 8644274039 scopus 로고    scopus 로고
    • A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL)
    • Nabhan C, Patton D, Gordon LI, et al. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2004;45:2269-2273.
    • (2004) Leuk Lymphoma , vol.45 , pp. 2269-2273
    • Nabhan, C.1    Patton, D.2    Gordon, L.I.3
  • 107
    • 0038724252 scopus 로고    scopus 로고
    • Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies
    • Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003;101:3413-3415.
    • (2003) Blood , vol.101 , pp. 3413-3415
    • Faderl, S.1    Thomas, D.A.2    O'Brien, S.3
  • 108
    • 77952573871 scopus 로고    scopus 로고
    • Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence
    • Faderl S, Ferrajoli A, Wierda W, et al. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. Cancer. 2010;116:2360-2365.
    • (2010) Cancer , vol.116 , pp. 2360-2365
    • Faderl, S.1    Ferrajoli, A.2    Wierda, W.3
  • 109
    • 71649094833 scopus 로고    scopus 로고
    • Alemtuzumab and Rituximab Combination Therapy for Patients with Untreated CLL - a Phase II Trial
    • Abstract 2098
    • Frankfurt O, Hamilton E, Duffey S, et al. Alemtuzumab and Rituximab Combination Therapy for Patients with Untreated CLL - a Phase II Trial. Blood. 2008;112:Abstract 2098.
    • (2008) Blood , vol.112
    • Frankfurt, O.1    Hamilton, E.2    Duffey, S.3
  • 110
    • 55749093568 scopus 로고    scopus 로고
    • Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab
    • Zent CS, Call TG, Shanafelt TD, et al. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer. 2008;113:2110-2118.
    • (2008) Cancer , vol.113 , pp. 2110-2118
    • Zent, C.S.1    Call, T.G.2    Shanafelt, T.D.3
  • 111
    • 38049094162 scopus 로고    scopus 로고
    • Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL
    • Abstract 31
    • Wierda WG, O'Brien S, Faderl S, et al. Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL. Blood. 2006;108: Abstract 31.
    • (2006) Blood , vol.108
    • Wierda, W.G.1    O'Brien, S.2    Faderl, S.3
  • 112
    • 77950313690 scopus 로고    scopus 로고
    • Frontline Combined Chemoimmunotherapy with Fludarabine, Cyclophosphamide, Alemtuzumab and Rituximab (CFAR) in High-Risk Chronic Lymphocytic Leukemia
    • Abstract 208
    • Parikh SA, Keating M, O'Brien S, et al. Frontline Combined Chemoimmunotherapy with Fludarabine, Cyclophosphamide, Alemtuzumab and Rituximab (CFAR) in High-Risk Chronic Lymphocytic Leukemia. Blood. 2009;114:Abstract 208.
    • (2009) Blood , vol.114
    • Parikh, S.A.1    Keating, M.2    O'Brien, S.3
  • 113
    • 77449133613 scopus 로고    scopus 로고
    • Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia
    • Byrd JC, Kipps TJ, Flinn IW, et al. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia. Blood. 2010;115:489-495.
    • (2010) Blood , vol.115 , pp. 489-495
    • Byrd, J.C.1    Kipps, T.J.2    Flinn, I.W.3
  • 114
    • 0033034356 scopus 로고    scopus 로고
    • High dose methyl prednisolone in refractory chronic lymphocytic leukaemia
    • Thornton PD, Hamblin M, Treleaven JG, et al. High dose methyl prednisolone in refractory chronic lymphocytic leukaemia. Leuk Lymphoma. 1999;34:167-170.
    • (1999) Leuk Lymphoma , vol.34 , pp. 167-170
    • Thornton, P.D.1    Hamblin, M.2    Treleaven, J.G.3
  • 115
    • 0346258157 scopus 로고    scopus 로고
    • High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities
    • Thornton PD, Matutes E, Bosanquet AG, et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol. 2003;82:759-765.
    • (2003) Ann Hematol , vol.82 , pp. 759-765
    • Thornton, P.D.1    Matutes, E.2    Bosanquet, A.G.3
  • 116
    • 56249095457 scopus 로고    scopus 로고
    • Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia
    • Castro JE, Sandoval-Sus JD, Bole J, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia. 2008; 22:2048-2053.
    • (2008) Leukemia , vol.22 , pp. 2048-2053
    • Castro, J.E.1    Sandoval-Sus, J.D.2    Bole, J.3
  • 117
    • 55049110133 scopus 로고    scopus 로고
    • Efficacy of rituximab in combination with steroids in refractory chronic lymphocytic leukemia
    • Quinn JP, Mohamedbhai S, Chipperfield K, et al. Efficacy of rituximab in combination with steroids in refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2008;49:1995-1998.
    • (2008) Leuk Lymphoma , vol.49 , pp. 1995-1998
    • Quinn, J.P.1    Mohamedbhai, S.2    Chipperfield, K.3
  • 118
    • 37149029392 scopus 로고    scopus 로고
    • Methylprednisolone- rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features
    • Bowen DA, Call TG, Jenkins GD, Zent CS, et al. Methylprednisolone- rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma. 2007;48: 2412-2417.
    • (2007) Leuk Lymphoma , vol.48 , pp. 2412-2417
    • Bowen, D.A.1    Call, T.G.2    Jenkins, G.D.3    Zent, C.S.4
  • 119
    • 40849094878 scopus 로고    scopus 로고
    • High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy
    • Dungarwalla M, Evans SO, Riley U, et al. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica. 2008;93:475-476.
    • (2008) Haematologica , vol.93 , pp. 475-476
    • Dungarwalla, M.1    Evans, S.O.2    Riley, U.3
  • 120
    • 70350132633 scopus 로고    scopus 로고
    • Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia
    • Castro JE, Sandoval-Sus JD, Jain S, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia. 2009;23:1779-1789.
    • (2009) Leukemia , vol.23 , pp. 1779-1789
    • Castro, J.E.1    Sandoval-Sus, J.D.2    Jain, S.3
  • 121
    • 0033995976 scopus 로고    scopus 로고
    • Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia
    • Venugopal P, Sivaraman S, Huang XK, et al. Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leuk Res. 2000;24:411-415.
    • (2000) Leuk Res , vol.24 , pp. 411-415
    • Venugopal, P.1    Sivaraman, S.2    Huang, X.K.3
  • 122
    • 0036738061 scopus 로고    scopus 로고
    • Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms
    • Voso MT, Pantel G, Rutella S, et al. Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms. Haematologica. 2002;87:918-925.
    • (2002) Haematologica , vol.87 , pp. 918-925
    • Voso, M.T.1    Pantel, G.2    Rutella, S.3
  • 123
    • 67650879316 scopus 로고    scopus 로고
    • Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia
    • Ferrajoli A. Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50:514-516.
    • (2009) Leuk Lymphoma , vol.50 , pp. 514-516
    • Ferrajoli, A.1
  • 124
    • 77953384808 scopus 로고    scopus 로고
    • Experience with fludarabine, cyclophosphamide, rituximab (FCR) plus GM-CSF in frontline therapy for chronic lymphocytic leukemia (CLL)
    • Abstract 3173
    • Ferrajoli A, Faderl S, O'Brien S, et al. Experience with fludarabine, cyclophosphamide, rituximab (FCR) plus GM-CSF in frontline therapy for chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts). 2008;112:Abstract 3173.
    • (2008) Blood (ASH Annual Meeting Abstracts) , vol.112
    • Ferrajoli, A.1    Faderl, S.2    O'Brien, S.3
  • 125
    • 33947243663 scopus 로고    scopus 로고
    • Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study
    • Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24: 5343-5349.
    • (2006) J Clin Oncol , vol.24 , pp. 5343-5349
    • Chanan-Khan, A.1    Miller, K.C.2    Musial, L.3
  • 126
    • 45949100928 scopus 로고    scopus 로고
    • Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
    • Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111:5291-5297.
    • (2008) Blood , vol.111 , pp. 5291-5297
    • Ferrajoli, A.1    Lee, B.N.2    Schlette, E.J.3
  • 127
    • 51649123319 scopus 로고    scopus 로고
    • Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells
    • Wu L, Adams M, Carter T, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008;14: 4650-4657.
    • (2008) Clin Cancer Res , vol.14 , pp. 4650-4657
    • Wu, L.1    Adams, M.2    Carter, T.3
  • 128
    • 76149124676 scopus 로고    scopus 로고
    • Combination Therapy with Lenalidomide and Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)
    • Abstract 206
    • Ferrajoli A, Badoux XC, O'Brien S, et al. Combination Therapy with Lenalidomide and Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL). Blood. 2009;114:Abstract 206.
    • (2009) Blood , vol.114
    • Ferrajoli, A.1    Badoux, X.C.2    O'Brien, S.3
  • 129
    • 2942567554 scopus 로고    scopus 로고
    • Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule
    • Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood. 2004;103:4416-4423.
    • (2004) Blood , vol.103 , pp. 4416-4423
    • Ghielmini, M.1    Schmitz, S.F.2    Cogliatti, S.B.3
  • 130
    • 77958503335 scopus 로고    scopus 로고
    • Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy
    • Salles GA, Seymour JF, Feugier P, et al. Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy. J Clin Oncol. 2010; 28:8004.
    • (2010) J Clin Oncol , vol.28 , pp. 8004
    • Salles, G.A.1    Seymour, J.F.2    Feugier, P.3
  • 131
    • 33749545033 scopus 로고    scopus 로고
    • Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial
    • van Oers MHJ, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108:3295-3301.
    • (2006) Blood , vol.108 , pp. 3295-3301
    • van Oers, M.H.J.1    Klasa, R.2    Marcus, R.E.3
  • 132
    • 37549046061 scopus 로고    scopus 로고
    • Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia
    • Del Poeta G, Del Principe MI, Buccisano F, et al. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer. 2008; 112:119-128.
    • (2008) Cancer , vol.112 , pp. 119-128
    • Del Poeta, G.1    Del Principe, M.I.2    Buccisano, F.3
  • 133
    • 77953473091 scopus 로고    scopus 로고
    • Rituximab maintenance following chemoimmunotherapy improves outcome in B-cell chronic lymphocytic leukemia
    • Abstract 2364
    • Del Poeta G, Del Principe MI, Ragusa D, et al. Rituximab maintenance following chemoimmunotherapy improves outcome in B-cell chronic lymphocytic leukemia. Blood. 2009;114:Abstract 2364.
    • (2009) Blood , vol.114
    • del Poeta, G.1    Del Principe, M.I.2    Ragusa, D.3
  • 134
    • 34547483328 scopus 로고    scopus 로고
    • Long-term treatment with rituximab is feasible in selected patients with B-CLL: Responseadjusted low-dose maintenance treatment with rituximab in patients with relapsed B-CLL, who achieved a partial or minimal response to prior rituximab therapy
    • Srock S, Schriever F, Neubauer A, et al. Long-term treatment with rituximab is feasible in selected patients with B-CLL: responseadjusted low-dose maintenance treatment with rituximab in patients with relapsed B-CLL, who achieved a partial or minimal response to prior rituximab therapy. Leuk Lymphoma. 2007;48:905-911.
    • (2007) Leuk Lymphoma , vol.48 , pp. 905-911
    • Srock, S.1    Schriever, F.2    Neubauer, A.3
  • 135
    • 70349260657 scopus 로고    scopus 로고
    • Improving survival in patients with chronic lymphocytic leukemia (1980-2008): The Hospital Clinic of Barcelona experience
    • Abrisqueta P, Pereira A, Rozman C, et al. Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. Blood, 2009;114:2044-2050.
    • (2009) Blood , vol.114 , pp. 2044-2050
    • Abrisqueta, P.1    Pereira, A.2    Rozman, C.3
  • 136
    • 46749134890 scopus 로고    scopus 로고
    • Trends in long-term survival of patients with chronic lymphocytic leukemia from the early 21st century
    • Brenner H, Gonolons A, Pulte D. Trends in long-term survival of patients with chronic lymphocytic leukemia from the early 21st century. Blood, 2008;111:4916-4921.
    • (2008) Blood , vol.111 , pp. 4916-4921
    • Brenner, H.1    Gonolons, A.2    Pulte, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.